Overview

Gender

male

For nearly 10 years, Andy has worked in research and therapeutic development using small molecules, biologics, and small RNAs to target autoimmune, cardio-renal, and gastrointestinal disease.

As an early employee at Ardelyx, he established a multidisciplinary R&D laboratory and managed the RDX5791/AZD1722 program from discovery phase through Phase 2a. He is now working broadly on AZD1722 development through the Ardelyx partnership with AstraZeneca.

Andy holds a B.S. in Chemistry from Hope College and a Ph.D. in Biochemistry from Michigan State University. He was an NIH Postdoctoral Fellow at the Howard Hughes Medical Institute (University of Colorado at Boulder) and the University of Wisconsin at Madison.